A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Latest Information Update: 19 Dec 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Inflammatory breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Biomarker; Proof of concept; Therapeutic Use
- 15 Nov 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2028.
- 15 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2028.
- 06 Jun 2023 Results (n=43, between 2015 and 2022 ), presented at the 59th Annual Meeting of the American Society of Clinical Oncology.